Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George D Demetri

Showing results (1-10 of 232) with videos related to

Pageof 24
Sort By:
Clinical Advances in Hematology & Oncology : H&O|March 3, 2012
mTOR inhibitors in sarcomaGeorge D Demetri
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare diseaseGeorge D Demetri
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)George D Demetri
Cancer Investigation|August 29, 2002
GIST 1, chemotherapy 0, with a brand new hitter up nextGeorge D Demetri
The Journal of Clinical Investigation|December 7, 2007
Structural reengineering of imatinib to decrease cardiac risk in cancer therapyGeorge D Demetri
Oncology|December 17, 2018
Evolution of the International Sarcoma Community: A Personal PerspectiveGeorge D Demetri
Clinical Advances in Hematology & Oncology : H&O|April 28, 2009
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GISTGeorge D Demetri
Clinical Advances in Hematology & Oncology : H&O|October 23, 2010
Disease state awareness in sarcomaGeorge D Demetri
Seminars in Oncology|March 23, 2011
Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumorsGeorge D Demetri
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Reply to S. Rastogi et alGeorge D Demetri
Pageof 24

Showing results (1-10 of 232) with videos related to

Sort By:
Pageof 24
Clinical Advances in Hematology & Oncology : H&O|March 3, 2012
mTOR inhibitors in sarcomaGeorge D Demetri
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare diseaseGeorge D Demetri
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)George D Demetri
Cancer Investigation|August 29, 2002
GIST 1, chemotherapy 0, with a brand new hitter up nextGeorge D Demetri
The Journal of Clinical Investigation|December 7, 2007
Structural reengineering of imatinib to decrease cardiac risk in cancer therapyGeorge D Demetri
Oncology|December 17, 2018
Evolution of the International Sarcoma Community: A Personal PerspectiveGeorge D Demetri
Clinical Advances in Hematology & Oncology : H&O|April 28, 2009
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GISTGeorge D Demetri
Clinical Advances in Hematology & Oncology : H&O|October 23, 2010
Disease state awareness in sarcomaGeorge D Demetri
Seminars in Oncology|March 23, 2011
Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumorsGeorge D Demetri
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Reply to S. Rastogi et alGeorge D Demetri
Pageof 24